Medarex Inc., of Princeton, N.J., said it will receive an undisclosed milestone payment from licensing partner Centocor Ortho Biotech Inc., of Horsham, Pa., in connection with the marketing approval in Canada of Simponi (golimumab) as a once-monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Galapagos, of Mechelen, Belgium, initiated Phase I development of its small-molecule GLPG0259 for rheumatoid arthritis...The compound is part of Galapagos' internal rheumatoid arthritis program, which is part of an alliance with Janssen Pharmaceutica, of Titusville, N.J., a Johnson & Johnson company

Lodotra is a delayed-release, low-dose prednisone tablet recommended for European approval in January in rheumatoid arthritis and associated morning stiffness

The goal is to develop a recombinant human alkaline phosphatase using the human CAP cell line useful in major chronic diseases such as rheumatoid arthritis

The goal is to develop a recombinant human alkaline phosphatase using the human CAP cell line useful in major chronic diseases such as rheumatoid arthritis

It also will support ongoing programs under its collaboration with Madison, N.J.-based Wyeth, including TRU-015 in rheumatoid arthritis (RA) and SBI-087 in RA and lupus

UCB SA, of Brussels, Belgium, said the FDA is not requiring any further clinical or nonclinical studies for its biologics license application (BLA) for Cimzia in rheumatoid arthritis...UCB in January received a complete response letter from the FDA on Cimzia's BLA for rheumatoid arthritis

UCB SA, of Brussels, Belgium, said the FDA is not requiring any further clinical or nonclinical studies for its biologics license application (BLA) for Cimzia in rheumatoid arthritis...The company in January received a complete response letter from the FDA on Cimzia's BLA for rheumatoid arthritis

Those programs include PN 400, which is partnered with London-based AstraZeneca plc and is a fixed-dose combination of enteric-coated naproxen with immediate-release esomeprazole in development for treating symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk for developing NSAID-associated gastric ulcers

The company also said it plans to focus further development of atiprimod, which it acquired from Cambridge, Mass.-based Genzyme Corp.'s AnorMED subsidiary, on rheumatoid arthritis

Lexicon has two drug candidates in Phase II development, LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome, and two drug candidates in Phase I trials, LX2931 for rheumatoid arthritis and LX4211 for diabetes

Hoffmann-La Roche Ltd., of Basel, Switzerland, said the European Commission approved RoActemra (tocilizumab) for rheumatoid arthritis

Funds will be used to advance the development of drugs in cancer and inflammatory diseases such as rheumatoid arthritis and psoriasis

UCB SA, of Brussels, Belgium, said the FDA issued a complete response letter for Cimzia (certolizumab pegol), a pegylated antitumor necrosis factor compound, in rheumatoid arthritis, and requested a new safety update with all clinical data, including data generated since the company filed the biologics license applications...Cimzia, which is approved in Crohn's disease, also is under review in Europe for treating rheumatoid arthritis

UCB SA, of Brussels, Belgium, said the FDA issued a complete response letter for Cimzia (certolizumab pegol), a pegylated antitumor necrosis factor compound, in rheumatoid arthritis, and requested a new safety update with all clinical data, including data generated since the company filed the biologics license applications...Cimzia, which is approved in Crohn's disease, also is under review in Europe for treating rheumatoid arthritis

Roche Holding AG, of Basel, Switzerland, said the FDA has asked for additional nonclinical animal model data for the firm's investigational rheumatoid arthritis drug Actemra (tocilizumab) beyond what was included in the drug's biologics license application, submitted Nov. 18, 2007

MorphoSys AG, of Martinsried, Germany, said preclinical data showed that MOR103, a fully human HuCAL antibody directed against GM-CSF, inhibited the signs and symptoms of rheumatoid arthritis (RA) in vivo in a dose-dependent manner

Cel-Sci Corp., of Vienna, Va., said data from animal studies showed that its rheumatoid arthritis vaccine CEL-2000 prevented or retarded the permanent tissue damage caused by RA

MorphoSys AG, of Martinsried, Germany, said preclinical data showed that MOR103, a fully human HuCAL antibody directed against GM-CSF, inhibited the signs and symptoms of rheumatoid arthritis (RA) in vivo in a dose-dependent manner